Published in Antimicrob Agents Chemother on February 01, 1992
Effect of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses. Antimicrob Agents Chemother (1994) 0.93
Effect of sucralfate on absorption of norfloxacin and ofloxacin. Antimicrob Agents Chemother (1994) 0.87
Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother (1994) 0.87
The effect of ferrous sulphate on the absorption of norfloxacin, ciprofloxacin and ofloxacin. Br J Clin Pharmacol (1994) 0.86
Effects of milk and food on the absorption of enoxacin. Br J Clin Pharmacol (1995) 0.75
The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers. Drugs (1995) 0.75
Fluoroquinolone antimicrobial agents. N Engl J Med (1991) 4.65
Ofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1987) 2.95
Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther (1989) 2.08
Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother (1989) 1.98
Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs (1985) 1.56
Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet (1990) 1.48
Interactions affecting drug absorption. Clin Pharmacokinet (1985) 1.44
Inhibition of norfloxacin absorption by antacids. Antimicrob Agents Chemother (1990) 1.38
Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast. J Clin Pharmacol (1989) 1.35
Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther (1991) 1.32
Interactions with the absorption of tetracyclines. Drugs (1976) 1.29
A simple isocratic high-pressure liquid chromatographic assay of quinolones in serum. J Antimicrob Chemother (1989) 1.10
The clinical significance of food-drug interactions: a review. Med J Aust (1989) 1.00
Comparison of activated charcoal and ipecac syrup in prevention of drug absorption. Eur J Clin Pharmacol (1983) 2.09
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (1998) 2.09
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 2.01
Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2007) 1.96
Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clin Pharmacokinet (1983) 1.89
Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol (1979) 1.82
Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet (1993) 1.70
UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther (2009) 1.67
Effect of diuretic, beta-adrenoceptor blocking agent and their combination on elevated blood pressure and serum potassium: a cross-over study. Br J Clin Pharmacol (1978) 1.62
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther (1997) 1.59
Haemodynamic and catecholamine responses to induction of anaesthesia and tracheal intubation: comparison between propofol and thiopentone. Br J Anaesth (1993) 1.54
Local infiltration analgesia with levobupivacaine compared with intrathecal morphine in total hip arthroplasty patients. Acta Anaesthesiol Scand (2012) 1.53
Methionine in paracetamol tablets, a tool to reduce paracetamol toxicity. Int J Clin Pharmacol Ther Toxicol (1985) 1.50
Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1998) 1.49
A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther (1993) 1.45
Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther (1998) 1.42
Cyclosporine A increases plasma concentrations and effects of repaglinide. Am J Transplant (2006) 1.40
Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther (2001) 1.40
Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther (1996) 1.39
Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man. Eur J Clin Pharmacol (1980) 1.38
ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther (2009) 1.38
Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther (1999) 1.34
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol (1998) 1.33
The effects of the systemic antimycotics, itraconazole and fluconazole, on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Anesth Analg (1996) 1.31
Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 1.30
Reduction of absorption of digoxin, phenytoin and aspirin by activated charcoal in man. Eur J Clin Pharmacol (1978) 1.29
Interactions with the absorption of tetracyclines. Drugs (1976) 1.29
Sotalol and prolonged Q-Tc interval. Lancet (1981) 1.27
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia (2003) 1.27
Interference of iron with the absorption of tetracyclines in man. Br Med J (1970) 1.25
Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. Br J Clin Pharmacol (1998) 1.24
Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther (2000) 1.24
Bacterial pneumonia can increase serum concentration of clozapine. Eur J Clin Pharmacol (2002) 1.22
Bioavailability and central side effects of different carbamazepine tablets. Int J Clin Pharmacol Ther Toxicol (1985) 1.22
Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias. Eur Heart J (1981) 1.20
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther (2001) 1.19
Drug-related deaths in a university central hospital. Eur J Clin Pharmacol (2002) 1.18
The transplacental transfer of the macrolide antibiotics erythromycin, roxithromycin and azithromycin. BJOG (2000) 1.17
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther (2007) 1.16
Itraconazole decreases renal clearance of digoxin. Ther Drug Monit (1997) 1.16
Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther (1998) 1.13
Inhibitory effect of various iron salts on the absorption of tetracycline in man. Eur J Clin Pharmacol (1974) 1.11
Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol (1994) 1.11
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol (2001) 1.08
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia (2003) 1.06
Sotalol intoxication with prolonged Q-T interval and severe tachyarrhythmias. Br Med J (1979) 1.05
Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother (2001) 1.05
Cimetidine-phenytoin interaction: effect on serum phenytoin concentration and antipyrine test. Eur J Clin Pharmacol (1981) 1.05
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos (2001) 1.04
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos (2000) 1.04
Stereospecificity in some central and circulatory effects of phenylisopropyl-adenosine (PIA). Arzneimittelforschung (1975) 1.04
Rifampin decreases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther (2000) 1.04
Antipyretic analgesics in patients on antiepileptic drug therapy. Eur J Clin Pharmacol (1979) 1.03
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther (2000) 1.03
Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosis. Aliment Pharmacol Ther (2006) 1.02
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clin Pharmacol Ther (2001) 1.00
Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther (1995) 0.99
Effect of route of administration of fluconazole on the interaction between fluconazole and midazolam. Eur J Clin Pharmacol (1997) 0.99
Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol (1980) 0.99
Effect of zinc sulphate on the absorption of tetracycline and doxycycline in man. Eur J Clin Pharmacol (1975) 0.98
Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther (1998) 0.98
Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol (2003) 0.98
Failure of oral activated charcoal to accelerate the elimination of amiodarone and chloroquine. Hum Exp Toxicol (1992) 0.98
A mechanistic, model-based approach to safety assessment in clinical development. CPT Pharmacometrics Syst Pharmacol (2012) 0.97
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J (2007) 0.97
Interaction between doxycycline and barbiturates. Br Med J (1974) 0.96
Antihypertensive effect of trimepranol, a new beta-blocking agent. Int J Clin Pharmacol Biopharm (1978) 0.96
Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Br J Anaesth (2011) 0.96
Assessment of beta-blocking activity of trimepranol in man. Int J Clin Pharmacol Biopharm (1978) 0.96
Pharmacokinetics of single-dose oral ciprofloxacin in infants and small children. Antimicrob Agents Chemother (1992) 0.96
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther (2008) 0.96
Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother (2000) 0.96
Prolonged Q-T interval and severe tachyarrhythmias, common features of sotalol intoxication. Eur J Clin Pharmacol (1981) 0.96
Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology (1999) 0.96
Effect of exercise on the serum level and urinary excretion of tetracycline, doxycycline and sulphamethizole. Eur J Clin Pharmacol (1977) 0.95
Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain (1996) 0.95
Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Clin Pharmacol Ther (2012) 0.95
A prospective study of acute poisonings in Finnish hospital patients. Hum Exp Toxicol (1998) 0.95
Triazolam is ineffective in patients taking rifampin. Clin Pharmacol Ther (1997) 0.94
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther (2001) 0.94
Phenothiazines and intestinal dilatation. Lancet (1969) 0.93
Antiepileptic drugs and alpha 1-acid glycoprotein. N Engl J Med (1982) 0.93
Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol (1998) 0.93
Iron-tetracycline interaction: effect of time interval between the drugs. Acta Med Scand (1972) 0.92
Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole. Pharmacol Toxicol (1999) 0.92
Bioavailability of four brands of phenytoin tablets. Eur J Clin Pharmacol (1975) 0.92
The effect of cholestyramine and activated charcoal on glipizide absorption. Br J Clin Pharmacol (1990) 0.92
Oral activated charcoal and dapsone elimination. Clin Pharmacol Ther (1980) 0.92
Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers. Br J Clin Pharmacol (1995) 0.92
Do gastric contents modify antidotal efficacy of oral activated charcoal? Br J Clin Pharmacol (1984) 0.92
Identification of drugs ingested in acute poisoning: correlation of patient history with drug analyses. Ther Drug Monit (2000) 0.92
Itraconazole increases plasma concentrations of quinidine. Clin Pharmacol Ther (1997) 0.92
Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol (2012) 0.91
Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur J Clin Pharmacol (1998) 0.91
Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther (1999) 0.91
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clin Pharmacol Ther (2008) 0.91
Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther (1998) 0.91
Concentrations and effects of buspirone are considerably reduced by rifampicin. Br J Clin Pharmacol (1998) 0.91